Hosted on MSN
Recursion Pharmaceuticals outlines focused R&D pipeline with multiple catalysts through 2026
CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript February 28, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.53 EPS, ...
Hello, and welcome, everybody, to Recursion's Q2 2025 Earnings Call. My name is Chris Gibson, and I'm the Co-Founder and CEO of Recursion. And I'm excited to share with you today some of the latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results